ArticleCureus2020
Factors Associated with Worse Outcome in Early Stage Gastric Cancer Using the Surveillance, Epidemiology, and End Results (SEER) Database.
Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Survival outcomes in early gastric cancer: evidence from SEER-based population studies.Journal of gastrointestinal oncology · 2026Article
- Predictive Mortality and Gastric Cancer Risk Using Clinical and Socio-Economic Data: A Nationwide Multicenter Cohort Study.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The benefit of adjuvant treatment in gastric adenocarcinoma patients with involvement of the muscularis propria but not beyond is unclear. We aim to establish a model that identifies the factors that adversely affect the prognosis in these patients. Methods We used the Surveillance, Epidemiology, and End Results (SEER) database to identify subjects with stage T2aN0M0 gastric adenocarcinoma who had tumor resection between 2004 and 2015. Data pertaining to the following variables were collected: age, gender, ethnicity, tumor size, grade, site, number of lymph nodes (LNs) being examined, and extent of surgery. Results A total of 1307 patients met our inclusion criteria. The five-year overall survival (OS) was 65%. The following factors were significantly associated with a shorter OS in univariate analysis. Age > 60 years, non-Hispanic whites and non-Hispanic blacks, patients with less than 15 lymph nodes examined at the time of surgery, tumors at the fundus and cardia of the stomach, and those who underwent endoscopic resection or had partial esophagectomy. On multivariate Cox regression, the following factors were predictors for worse OS: age > 60 years with a hazards ratio (HR) = 2.03 (95% CI: 1.49-2.76), patients with less than 15 lymph nodes examined with HR = 1.72 (95% CI: 1.34-2.20), non-Hispanic whites and non-Hispanic blacks with HR = 1.62 (95% CI: 1.26-2.08), and tumors within the cardia and fundus of the stomach with HR = 1.51 (95% CI: 1.21-1.89). Conclusion Patients with stage T2aN0M0 gastric cancer who had their tumor located at the cardia or fundus of the stomach or those with inadequate lymph nodes resection had inferior survival and could potentially benefit from adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.